Development of Cagrilintide, a Long-Acting Amylin Analogue
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
) and some of the structure-activity efforts that led to the selection of this analogue for clinical development with obesity as an indication. Cagrilintide is currently in clinical trial and has induced significant weight loss when dosed alone or in combination with the GLP-1 analogue semaglutide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Rybelsus is an oral form of semaglutide, a modified GLP-1 analog in which the native peptide has been engineered for both enzymatic stability and albumin binding: specifically, an Aib (α-aminoisobutyric acid) substitution at position 8 to resist DPP-4 degradation and an attached C18 fatty diacid chain at lysine 26 (via a spacer) to promote reversible albumin binding and extend half-life [63].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [63]
In the citing paper
“Cagrilintide acts on amylin and calcitonin receptors within the area of the postrema and nucleus tractus solitarius, lowering food intake through both homeostatic and hedonic mechanisms. It slows gastric emptying, suppresses postprandial glucagon secretion, and reduces appetite via central hypothalamic pathways [63].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [63]
In the citing paper
“Amylin may promote weight reduction and increase sensitivity to leptin in patients with obesity.”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [169]
In the citing paper
“Cagrilintide is a long-acting amylin analogue [169,164].”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [169]
In the citing paper
“A closely related long-acting amylin analogue, cagrilintide has recently been shown to reduce body weight by about 10% at doses of 2.4 mg and 4.5 mg injected subcutaneously once weekly during a 26-week study in overweight and obese individuals [41,42].”
From Recent advances in peptide-based therapies for obesity and type 2 diabetes (2024) · cites this paper as [41]
Citations
Cites
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105
Self-citationThe Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Pratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein
Zhang, Y., Sun, B., Feng, D., Hu, H., Chu, M., Qu, Q., Tarrasch, J. T., Li, S., Sun Kobilka, T., Kobilka, B. K., et al. (2017) · Nature · doi:10.1038/nature22394 · Cited by 576
Capehorn, M. S., Catarig, A.-M., Furberg, J. K., Janez, A., Price, H. C., Tadayon, S., Vergès, B., & Marre, M. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.101117 · Cited by 412
Enebo, L. B., Berthelsen, K. K., Kankam, M., Lund, M. T., Rubino, D. M., Satylganova, A., & Lau, D. C. W. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00845-x · Cited by 316
In Vivo Seeding and Cross-Seeding of Localized Amyloidosis
Oskarsson, M. E., Paulsson, J. F., Schultz, S. W., Ingelsson, M., Westermark, P., & Westermark, G. T. (2015) · The American Journal of Pathology · doi:10.1016/j.ajpath.2014.11.016 · Cited by 281
Cryo-EM structure of the active, Gs-protein complexed, human CGRP receptor
Liang, Y.-L., Khoshouei, M., Deganutti, G., Glukhova, A., Koole, C., Peat, T. S., Radjainia, M., Plitzko, J. M., Baumeister, W., Miller, L. J., et al. (2018) · Nature · doi:10.1038/s41586-018-0535-y · Cited by 238
Lutz, T., Mollet, A., Rushing, P., Riediger, T., & Scharrer, E. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801664 · Cited by 223
Research works printed but not linked: 2
- Srinivasan A., 2020, J. Musculoskelet. Neuronal Interact., 20, 600
- World Health Organization. International nonproprietary names for pharmaceutical substances (INN), Drug Information, 2020; Vol. 34, pp 263–301. https://www.who.int/docs/default-source/international-nonproprietary-names-(inn)/pl123.pdf (accessed 9 Feb 2021).
Cited by
GLP-1 physiology informs the pharmacotherapy of obesity
Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101351 · Cited by 510
Lau, D. C. W., Erichsen, L., Francisco, A. M., Satylganova, A., le Roux, C. W., McGowan, B., Pedersen, S. D., Pietiläinen, K. H., Rubino, D., & Batterham, R. L. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01751-7 · Cited by 278
GLP-1-based therapies for diabetes, obesity and beyond
Drucker, D. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01183-8 · Cited by 236
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
Garvey, W. T., Blüher, M., Osorto Contreras, C. K., Davies, M. J., Winning Lehmann, E., Pietiläinen, K. H., Rubino, D., Sbraccia, P., Wadden, T., Zeuthen, N., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2502081 · Cited by 238
Recent advances in the development of therapeutic peptides
Fetse, J., Kandel, S., Mamani, U., & Cheng, K. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.04.003 · Cited by 179
Metadata
- Authors
- Kruse, T., Hansen, J. L., Dahl, K., Schäffer, L., Sensfuss, U., Poulsen, C., Schlein, M., Hansen, A. M. K., Jeppesen, C. B., Dornonville de la Cour, C., Clausen, T. R., Johansson, E., Fulle, S., Skyggebjerg, R. B., & Raun, K.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk, Novo Nordisk Park, DK-2760 Maaloev, Denmark
- Corresponding author
- Kruse, Thomas
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-07-21
- Volume
- 64
- Issue
- 15
- Pages
- 11183-11194
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W3187035249
- Cited by
- 129
- References
- 42
- Citations by year
- 2026: 27 · 2025: 40 · 2024: 26 · 2023: 19 · 2022: 14 · 2021: 3
- FWCI
- 9.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Medicinal Chemistry (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- cagrilintide, amylin analogues, long-acting insulin analogues, obesity, weight loss, semaglutide, GLP-1 receptor agonists, structure-activity relationship, clinical development
- MeSH terms
- Drug Development, Dose-Response Relationship, Drug, Humans, Hypoglycemic Agents, Models, Molecular, Structure-Activity Relationship, Molecular Structure, Islet Amyloid Polypeptide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of Cagrilintide, a Long-Acting Amylin Analogue. https://app.cochat.ai/papers/10.1021/acs.jmedchem.1c00565
- The paper
- Kruse, T., Hansen, J. L., Dahl, K., Schäffer, L., Sensfuss, U., Poulsen, C., Schlein, M., Hansen, A. M. K., Jeppesen, C. B., Dornonville de la Cour, C., Clausen, T. R., Johansson, E., Fulle, S., Skyggebjerg, R. B., & Raun, K. (2021). Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.1c00565
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.